Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13239MR)

This product GTTS-WQ13239MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13239MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8743MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ15310MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ14847MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ6051MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ12939MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ9939MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ6200MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ11584MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW